



**ADVANCING HEALTHCARE  
FOR A BETTER TOMORROW**

---

# ADVANCING HEALTHCARE FOR A BETTER TOMORROW

INNOVATING MEDICINE, ENHANCING LIVES.

In the journey of time, some beginnings stand as milestones, moments that shape the future and define the essence of leadership.

Since its inception, SPIMACO has been more than a national pharmaceutical manufacturer; it has been a promise of trust, a bridge between need and safety, and a symbol of a nation whose ambition knows no bounds.

With a vision rooted in the belief that health is a right for all, we have invested in knowledge, built advanced manufacturing facilities, and forged global partnerships to create a story that does not pause at the present but extends to shape tomorrow.

This is [SPIMACO](#), where medicine becomes a message, manufacturing a responsibility, and the homeland an endless source of inspiration.



## About Us

Since its inception, SPIMACO has been at the forefront of Saudi Arabia's pharmaceutical industry, embodying a bold vision to innovate high-quality medicines and strengthen healthcare security.

As the largest national manufacturer of pharmaceuticals and medical supplies in the region, SPIMACO delivers innovative and reliable solutions to meet the needs of patients and communities both locally and globally.

Supported by an extensive network of subsidiaries and strategic partnerships, SPIMACO's footprint spans regional and international markets, with an unwavering commitment to drug security, public health, and shaping a sustainable future for healthcare, in line with Saudi Arabia's Vision 2030.

# Our Vision

To become the top pharmaceutical firm in the Middle East and North Africa and a powerful worldwide force with a wide range of high-quality products in accordance with Vision 2030.

# Our Mission

We are dedicated to producing value for our stakeholders by giving back to our communities, ensuring patients' well-being, and providing creative and sustainable solutions.

# Our Values



Integrity



Innovation



Equal opportunities



Performance excellence



# Our Story



1986

SPIMACO was launched

1990

First products manufactured

Ministry of Health contract to produce first six products

1993

SPIMACO listed on the Saudi Stock Market

Exports to overseas markets

1998

Drug development center in Qassim

2018

Operation of the automated warehouse

Dammam Pharma SFDA Approval

2020

Oncology market products

2022

High Potent Plant opened

2023

Strategic plan launched

2024

Launching First Biosimilar Product

2025

Launching First Oncology Product from the High-Potent Facility



# Firgures to know



No. **1** MARKET LEADER  
IN SAUDI ARABIA



Over **+2.3bn**  
Units Produced



**21** Presence  
in KSA and other  
MENA Countries




**6.4%**  
KSA Market Share



Over **1,200+**  
Employees



Over **400+**  
Products Locally  
Manufactured





# Awards & Recognition



**Awarded The  
Most Innovative  
Company in  
Healthcare**

**in Saudi Arabia 2024**

By the Research Development  
and Innovation Authority



**Awarded The  
Best  
Pharmaceutical  
Company**

**in Saudi Arabia 2024**

GBO Awards

# SPIMACO

## Geographical Presence



### MANUFACTURING PLANTS IN

- Qassim Complex
- CAD API Manufacturing
- SPIMACO MISR
- Berrechid
- High Potent Facility
- Dammam Pharma
- Tangier
- TAPHCO Algeria

### PROMOTION & DISTRIBUTION

- Saudi Arabia
- UAE
- Kuwait
- Bahrain
- Oman
- Qatar
- Yemen
- Iraq
- Egypt
- Jordan
- Sudan
- South Sudan
- Algeria
- Morocco
- Libya
- Lebanon
- Ethiopia
- Tanzania
- Uganda
- Kenya
- Nigeria



# SPIMACO GROUP Structure



**Qassim Manufacturing Complex**  
Equity Share:  
**100%**



**ARACOM**  
Equity Share:  
**100%**



**Qassim Medical Services**  
Equity Share:  
**57.22%**



**CAD Middle East (API)**  
Equity Share:  
**44%**



**Dammam Pharma**  
Equity Share:  
**100%**



**SPIMACO MISR**  
Equity Share:  
**91%**



**ENAYAH**  
Equity Share:  
**60%**



**TAPHCO Algeria**  
Equity Share:  
**22%**



**ARAC**  
Equity Share:  
**100%**



**SPIMACO MAROCO**  
Equity Share:  
**79%**



**SPIMACO EGYPT**  
Equity Share:  
**100%**



**SPIMACO ALGERIE**  
Equity Share:  
**100%**

# Qassim Manufacturing Complex

## Overview

Located in Qassim Industrial City, the Qassim Manufacturing Complex is a cornerstone of SPIMACO's integrated pharmaceutical manufacturing capabilities. Spanning 150,000 square meters with 60,000 square meters of built-up area, the facility is equipped with cutting-edge technologies and staffed by more than 500 highly skilled professionals. Certified by Good Manufacturing Practices (GMP), the complex produces a diverse portfolio that includes tablets, capsules, syrups, injections, creams, and gels. With a strong focus on chronic disease management, antibiotics, and over-the-counter (OTC) medications, it serves as a key supplier to the domestic Saudi market as well as the wider GCC region.





# High Potent Facility

## Overview

The High Potent Facility represents one of SPIMACO's most advanced investments in specialized pharmaceutical manufacturing. Purpose-built for high-potent solid dosage forms, including tablets and capsules, the facility was granted approval by the Saudi Food and Drug Authority (SFDA), underscoring its commitment to world-class standards of quality and safety. The site addresses critical therapeutic areas such as oncology, nephrology, multiple sclerosis, and hepatology. Moreover, the facility has solidified SPIMACO's strategic partnership, further positioning the company as a key player in advanced pharmaceutical manufacturing in Saudi Arabia and beyond.



# CAD Middle East (API)

## Overview

CAD Middle East Pharmaceutical Industries LLC is a state-of-the-art manufacturing facility dedicated to producing the highest quality Active Pharmaceutical Ingredients (APIs). Established with the vision of becoming a leading local manufacturer, the facility leverages innovation, advanced technology, and the highest compliance standards to ensure drug security in KSA. Its diverse API portfolio spans antibiotics, antidiabetics, antipsychotics, antivirals, antihypertensives, cardiovascular, and CNS drugs, all approved by the SFDA, with additional certifications from BGMP, EQM, and WHO for international markets. Operating across KSA and neighboring countries, the company is expanding its presence in the GCC and Europe, supported by a robust in-house R&D pipeline set to drive significant growth in the near future.





# Dammam Pharma

## Overview

Dammam Pharma is a leading Saudi pharmaceutical company founded in 2012, dedicated to advancing healthcare and supporting local manufacturing excellence. Operating from a 16,000 m<sup>2</sup> state-of-the-art facility in Dammam First Industrial City, the company produces high-quality oral solid dosage forms, including tablets and capsules. Since 2017, Dammam Pharma has been delivering both generic and under-license products in collaboration with leading multinational partners, strengthening the Kingdom's pharmaceutical capabilities and aligning with its healthcare vision.



# ENAYAH

## Overview

Arabian Medical Products Manufacturing Company (ENAYAH), a joint venture of SPIMACO, is the licensed local manufacturer of Halyard Health disposable medical products. Established in 1991, the company produces a comprehensive range of single-use healthcare solutions, including surgical gowns, procedure packs, sterilization wraps, and protective apparel. Equipped with advanced manufacturing and sterilization facilities, ENAYAH ensures high-quality, safe, and reliable products that meet diverse healthcare needs.





# SPIMACO MISR

## Overview

SPIMACO MISR serves as SPIMACO's key branch in Egypt, specializing in the marketing, distribution, and manufacturing of pharmaceuticals and consumer healthcare products. Located in Alexandria Governorate, the facility features an advanced production site in Borg El Arab Industrial City, focusing on oral dosage forms such as tablets and capsules. SPIMACO MISR is dedicated to producing and marketing pharmaceuticals tailored to the Egyptian market, with key therapeutic areas including diabetes, cardiovascular diseases, and gastrointestinal disorders.





# SPIMACO Morocco

## Overview

SPIMACO Morocco serves as SPIMACO's key branch in North Africa, specializing in the marketing, distribution, and manufacturing of pharmaceuticals and consumer healthcare products. The branch operates two main production facilities in Tangier and Berrechid, focusing on local manufacturing and distribution to meet national and regional market needs. Its product portfolio includes chronic disease treatments, over-the-counter (OTC) medicines, and specialized products designed for regional requirements. SPIMACO Morocco serves as a strategic hub for North African market penetration, strengthening the company's presence across the region.





# SPIMACO Algeria

## Overview

SPIMACO Algeria serves as SPIMACO's key branch in North Africa, specializing in the import and distribution of pharmaceutical products within Algeria. The branch operates a head office and warehouse in Algiers, supported by an efficient supply chain tailored to the needs of the Algerian market. Its product portfolio includes chronic disease medications, antibiotics, and vitamins imported from SPIMACO's facilities in Saudi Arabia, ensuring reliable and high-quality pharmaceutical solutions for the Algerian market.



# Arac Healthcare

## Overview

Arac Healthcare serves as SPIMACO's primary sales and distribution arm for both its own products and foreign pharmaceuticals, while also developing a growing cosmeceutical portfolio. The company focuses on healthcare services and the distribution of medical supplies, providing hospitals, clinics, and healthcare providers with equipment and consumables, while supporting SPIMACO's pharmaceutical products. Arac Healthcare's competitive edge lies in delivering integrated healthcare solutions that combine pharmaceutical and non-pharmaceutical offerings, backed by reliable partnerships with leading medical device manufacturers. The company maintains a strong presence across Saudi Arabia with an expanding footprint in the region.





# Aracom Medical

## Overview

Aracom Medical is an SFDA-licensed pharmaceutical wholesaler and supplier, specializing in serving SPIMACO's small and medium-sized client base. The company focuses on strategic distribution and logistics for pharmaceuticals, acting as a critical link in SPIMACO's supply chain to ensure timely delivery across markets. Aracom Medical features advanced warehousing and inventory systems, along with nationwide and regional distribution networks covering Saudi Arabia and neighboring Gulf markets.



# ALQASSIM Medical Services

## Overview

ALQASSIM Medical Services is a closed Saudi Joint-Stock Company specializing in the ownership and management of hospitals and health centers across Saudi Arabia. The company focuses on owning, equipping, and managing healthcare facilities, in addition to manufacturing medical supplies and devices. Based in Buraydah City, Saudi Arabia, with potential expansion into the GCC, ALQASSIM Medical Services plays a strategic role in enhancing SPIMACO's influence on healthcare infrastructure and services within the Kingdom and the wider region.





# SPIMACO Group

## Products Portfolio Overview

SPIMACO’s portfolio spans a wide range of therapeutic areas, including Central Nervous System (CNS), Cardiovascular (CVS), Anti-infectives, Musculoskeletal, and Immunology/Oncology.

The portfolio also covers multiple technologies, such as high-potent products and biosimilars, delivered in diverse forms including orals, injectables, and topicals.

SPIMACO Portfolio	
Total: +600	Manufactured in SPIMACO
	533
	Licensors Products
	100

Future 5 years plan	
Total: 119	Manufactured in SPIMACO
	56
	Licensors Products
	63



# CAD API Capabilities

CAD has identified 54 APIs within current capabilities to be locally produced, significantly supporting the local pharmaceutical manufacturing ecosystem. This capability will enhance self-sufficiency and reduce dependency on imported APIs, aligning with national objectives for healthcare localization.

Category	No. of APIs	Manufacture Status	Product Mix Capacity Annual
Portfolio	17	Manufacture Now	300 MT
Pipeline	37	To be Registered & Manufactured	300 MT
Total			54





# Manufacturing Capabilities



Capsules



Tablets



Pre-filled Syringes




Sterile Ampoules & Vials



Antibiotics



Liquids



Suppositories



Medical Creams



Antiseptics



High-Potent &  
Oncology Products

# SPIMACO's Research & Development

**SPIMACO's Research & Development Department plays a pivotal role in driving innovation and excellence within the pharmaceutical industry.**

With a strong commitment to scientific advancement, the department focuses on developing new, high-quality pharmaceutical products while continuously enhancing existing formulations to address the evolving needs of patients and healthcare systems. Through cutting-edge research, advanced technologies, and strategic collaborations, SPIMACO's R&D serves as a cornerstone in shaping the company's future and reinforcing its leadership in pharmaceutical innovation.

It is dedicated to developing new, high-quality medicines and enhancing existing formulations to meet evolving healthcare needs. Through thorough research and the sourcing of premium ingredients, the department optimizes formulations and ensures stringent quality standards—delivering safe and effective therapies that enhance patient care.



R&D is the company's scientific branch that develops new generic products in-house and prepares technical files for registration with the SFDA and other export markets.

R&D offers technology transfer and technical support for both new and existing products, while also providing technical assistance to the company's affiliates.

R&D develops patented Non-infringing formulations and conducts clinical Bio-equivalence studies for its In-House developed formulations at CRO in human subjects for Dossier registrations with SFDA.

R&D assesses technology transfer products for localization by successfully transferring technology batches before carrying out stability studies and submitting files to the SFDA



# Endosa - First Biosimilar Manufactured in Saudi Arabia

1<sup>st</sup> SAUDI  
MADE  
Biosimilar

Endosa<sup>®</sup>  
Enoxaparin

SPIMACO's first biosimilar, approved by both the European Medicines Agency and the Saudi Food & Drug Authority, exemplifies the company's innovation and technical expertise.

This milestone involved a full technology transfer, including prefilled syringe technology, highlighting SPIMACO's capabilities in innovation, technical operations, and regulatory affairs. Building on this achievement, the company is actively working towards registration for export markets, further advancing its localization and global ambitions.



## SPIMACO Partnership from All Around the World





# Human Capital Development

At SPIMACO, the People & Culture sector plays a pivotal role in driving organizational excellence and enabling the company's growth ambitions. Through a comprehensive HR transformation journey, P&C has established a modern operating model built on three pillars: organizational effectiveness, digitalization, and culture transformation.

Our efforts focus on attracting and retaining top talent, implementing structured workforce planning, and advancing succession planning to secure future leadership. We have introduced new performance and reward frameworks, expanded learning and development programs, and launched tailored capability-building tracks that empower employees across all levels. Digital solutions such as SuccessFactors and automation initiatives are enhancing efficiency, transparency, and employee experience.

By fostering a high-performance, inclusive culture and positioning SPIMACO as an employer of choice, the People & Culture strategy contributes directly to Saudi Arabia's Vision 2030, ensuring our workforce is future-ready, engaged, and aligned with SPIMACO's mission of sustainable growth and international expansion.





# SPIMACO's Contribution to Saudi Vision 2030

SPIMACO's competitive advantage lies in its presence across the entire pharmaceutical value chain, covering research and development, manufacturing, and distribution.

This comprehensive integration not only enhances operational efficiency but also strengthens the company's role in achieving Saudi Arabia's Vision 2030 objectives. By localizing production and investing in advanced technologies, SPIMACO supports the Kingdom's pharmaceutical security strategy, aiming to reduce reliance on imports and ensure consistent access to essential and life-saving medicines.

Through its diversified portfolio and focus on high-potential areas such as oncology, biosimilars, and biologics, the company contributes to building a resilient healthcare ecosystem that meets both national priorities and regional market needs.



Research & Development



Active Pharma Ingredients (APIs)



Business Development



Distribution



Manufacturing



# Our Long-term Strategy Plan


In 2023, SPIMACO launched a revamped Patient-Centric long-term strategy focused on building the National Champion in the Saudi Pharma industry in line with Vision 2030 goals.

## Long-term Strategy Plan:

- Extend the company's leadership position in KSA and key regional markets
- Improve the wellbeing of patients
- Improve access to quality healthcare
- Bring long term benefits to all SPIMACO stakeholders
- Support the ambitions and aspirations of the Saudi Vision 2030



## The plan will be achieved through:





---

[www.spimaco.com.sa](http://www.spimaco.com.sa)